secwatch.observer — SEC 8-K summary
======================================

Issuer:     Clearside Biomedical, Inc. (CLSDQ)
CIK:        0001539029
Form:       8-K
Filed at:   2022-05-11T23:59:59+00:00
Accession:  0000950170-22-009366
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Clearside Biomedical Q1 2022 net loss $7.6M; CLS-AX cohort 4 enrolling
----------------------------------------------------------------------

- Net loss of $7.6M ($0.13 per share) vs $7.4M ($0.13) in Q1 2021; revenue $347K vs $34K.
- Cash and equivalents $34.4M; company expects sufficient for at least next 12 months.
- XIPERE (suprachoroidal triamcinolone) commercially launched in U.S. by Bausch + Lomb for uveitic macular edema.
- CLS-AX Phase 1/2a OASIS trial: Cohort 4 enrolling at 1.0 mg; no dose-limiting toxicities in Cohort 3; safety data expected Q4 2022.
- Benjamin R. Yerxa appointed to Board of Directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022009366/0000950170-22-009366-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1539029/000095017022009366/clsd-20220511.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-009366

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer